Case 2: 60-Year-Old Woman Following Induction Therapy for Active MM

Jointly provided by

Jointly provided by

Support for this activity has been provided through educational grants from Bristol-Myers Squibb; Celgene; Onyx Pharmaceuticals, an Amgen subsidiary; and Takeda Oncology.

Release date: 9/14/2015
Expiration date: 9/14/2016
Estimated time to complete: 30 minutes

Overview

Personalizing treatment regimens for multiple myeloma patients in both the frontline and salvage settings continues to pose a challenge for clinical oncologists, as newer therapeutic agents and combination treatments continue to expand the armamentarium. With this greater number of available agents comes the need for heightened attentiveness to identifying patients most likely to benefit from consolidation and maintenance therapies, effectively managing treatment-related toxicities, and selecting the most appropriate treatment upon relapse.

Case 2 resumes the case of Donna Medford, the patient introduced in Case 1. As a consultant on Donna’s case, your tasks will be to determine appropriate therapies and monitor her disease activity. This activity also features the Resource Library, which houses tools that can help clinicians more effectively manage patients with multiple myeloma.

Donna’s case begins with and can be reviewed in Multiple Myeloma Virtual Institute – Case 1: Adult Woman With Elevated Protein, which is available for additional CME credit at education.redmeded.com.

Faculty

Jesus G. Berdeja, MD
Sarah Cannon Research Institute
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists and medical oncologists involved in the care of patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess treatment response to induction therapy and determine which patients will benefit from consolidation and/or maintenance therapy
  • Select an appropriate course of therapy for patients who have relapsed from or become refractory to initial treatment
  • Anticipate and proactively manage disease- and treatment-related side effects and toxicities to maintain compliance with treatment at the dose and schedule that is optimal to achieve best response

Accreditation and Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure 

Penn State College of Medicine is committed to offering CME programs that promote improvements or quality in health care and are developed free of the control of commercial interests. Reasonable efforts have been taken to ensure that programs are balanced, independent, objective, scientific, and in compliance with regulatory requirements. Faculty, course directors, and planners have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest. Disclosure of a relationship is not intended to suggest or condone bias but is made to provide participants with information that might be of importance to their evaluation of this educational activity. Disclosures are as follows:

Jesus G. Berdeja, MD, has disclosed no relevant financial relationships.

Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Multiple Myeloma Research Foundation 
Staff involved in the development and review of this activity have disclosed no relevant financial relationships.

RedMedEd
Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships.
Lauren Showers, Project Manager, has disclosed no relevant financial relationships. 
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation do not recommend the use of any agent outside the labeled indications.

Disclaimer

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, Bristol-Myers Squibb, Celgene, Onyx Pharmaceuticals, an Amgen subsidiary, or Takeda Oncology. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in the activity. To receive CME credit, participants must review all activity information (including the learning objectives, disclosure statements, and content) and complete the posttest and program evaluation. Certificates can be printed immediately. 

For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5836-16-T.

Hardware/Software Requirements

  • Apple iPad or iPad mini (iOS 7 or higher) with an Internet connection
  • A computer with an Internet connection
    • Internet browser: Google Chrome, Internet Explorer 9 or higher, Firefox 26 or higher, or Safari 5 or higher
    • Additional software: Adobe Flash Player and/or an HTML 5-capable browser is required for video or audio playback; Adobe Acrobat Reader may occasionally be required

Privacy

This website is managed by RedMedEd, and RedMedEd’s privacy policy applies to this site. CME credit for this activity is provided by Penn State College of Medicine. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to Penn State College of Medicine to facilitate maintaining records concerning credits issued to you. RedMedEd may share aggregated data concerning registrations, posttests, and evaluations; no personally identifiable information will be knowingly shared. Penn State College of Medicine may use the information you provide on this site to contact you about your CME credit or other relevant educational activities provided through Penn State College of Medicine. For more information, contact ContinuingEd@hmc.psu.edu.